Related Experiment Video
Updated: Mar 12, 2026
07:58
qKAT: Quantitative Semi-automated Typing of Killer-cell Immunoglobulin-like Receptor Genes
Published on: March 6, 2019
9.1K
Expression efficiency of NAT2 haplotypes in a Korean population
Han Sung Na1, Jin Sol Lee, Hyun Sub Cheong
1Clinical Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Osong Health Technology Administration Complex.
Genes & Genetic Systems
|November 18, 2016
Summary
Single-nucleotide polymorphisms (SNPs) in NAT2 affect drug efficacy. This study found that common Korean NAT2 haplotypes influence enzyme expression, with Asian populations showing a higher prevalence of low-expression haplotypes, impacting personalized medicine.
Area of Science:
- Pharmacogenetics
- Genomics
- Biochemistry
Background:
- Single-nucleotide polymorphisms (SNPs) in the N-acetyltransferase 2 (NAT2) gene significantly influence the metabolism and efficacy of arylamine and hydrazine drugs.
- Understanding ethnic variations in NAT2 SNPs is crucial for advancing personalized medicine and optimizing drug therapy.
Purpose of the Study:
- To investigate the expression efficiency of NAT2 using promoter haplotypes prevalent in the Korean population.
- To evaluate the impact of specific NAT2 promoter haplotypes on enzyme activity.
Main Methods:
- Genotyping of seven key NAT2 promoter SNPs (rs4646241, rs4646242, rs4646243, rs4646267, rs4345600, rs4271002, rs4646246) in 192 Korean subjects.
- Construction of NAT2 promoter haplotypes based on genotyped SNPs.
- Luciferase assays were performed on the three most common haplotypes to quantify NAT2 enzyme expression levels.
Main Results:
- The most frequent Korean NAT2 haplotype (TACGAGG) exhibited the lowest enzyme expression (0.72 ± 0.06 RLU/β-galactosidase).
- The second (CGTAAGA) and third (TATAACA) most common haplotypes displayed intermediate (0.99 ± 0.05 RLU/β-galactosidase) and highest (1.45 ± 0.11 RLU/β-galactosidase) expression levels, respectively.
- Asian populations showed a higher frequency of the low-expression haplotype compared to Caucasian and African populations, whose haplotype frequencies differed significantly from the Korean ethnicity.
Conclusions:
- NAT2 promoter haplotypes significantly influence NAT2 enzyme expression levels in the Korean population.
- The prevalence of specific haplotypes, particularly those associated with lower enzyme activity, varies across ethnic groups, with implications for drug response.
- These findings contribute to a deeper understanding of NAT2 pharmacogenetics and support the development of ethnicity-specific personalized medicine strategies.
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
55
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
55
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
85
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
85
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
81
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
81
01:27Pharmacogenetics of Drug Metabolism: Overview
84
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
84
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
86
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
86